Targets › LHCGR
5 programs from 5 companies in 5 trials: 2 Phase 2, 2 Phase 3, 1 Phase 4; Genitourinary, Immunology, Metabolic and endocrine; next expected readout Nov 2026.
Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. (UniProt, P22888)
Open in Phaseline: the race on LHCGR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fundacion Clinic per a la Recerca Biomédica | Choriogonadotropin Alfa Luteinizing hormone/Choriogonadotropin receptor agonist | LHCGR | Phase 4 | Infertilities | Nov 2026 |
| Georgios Papadakis | Gonadotropin, Chorionic Luteinizing hormone/Choriogonadotropin receptor agonist | LHCGR | Phase 3 | Klinefelter Syndrome | Apr 2027 |
| Fundación para la Investigación del Hospital Clínico de Valencia | Gonadotropin, Chorionic Luteinizing hormone/Choriogonadotropin receptor agonist | LHCGR | Phase 3 | Low Ovarian Reserve | Jul 2027 |
| Clinique Ovo | HP-hMG (MENOPUR) Highly purified human menopausal gonadotrophin containing FSH and LH | FSHR, LHCGR | Phase 2 | IVF | Aug 2027 |
| Hospital Universitario Dr. Jose E. Gonzalez | Gonadotropin, Chorionic Luteinizing hormone/Choriogonadotropin receptor agonist | LHCGR | Phase 2 | Acute Graft Versus Host Disease | – |
Acute Graft Versus Host Disease (1) Infertilities (1) IVF (1) Low Ovarian Reserve (1) Klinefelter Syndrome (1)
small molecule (4), mixed (1)
Hospital Universitario Dr. Jose E. Gonzalez (1) Fundacion Clinic per a la Recerca Biomédica (1) Clinique Ovo (1) Fundación para la Investigación del Hospital Clínico de Valencia (1) Georgios Papadakis (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.